Pfizer Inc PFE

$27.80 -0.32 (-1.14%)

Valuation

Market cap
158,450,928,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.22
Forward PE
9.45
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
35,007,800
Avg volume
36,037,438
Day's range
$27.44 – $28.16
Shares out
5,699,674,000
Stochastic %K
24%
Beta
0.32
Analysts
Sell
Price target
$28.95

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

taxplanr Oct 4, 10:57 AM
Israel covered up hundreds of COVID vaccine deaths as well as the CDC $MRNA $PFE $BNTX https://www.instagram.com/reel/DdwQNxpRRRQ/?stkn=cnpuaDBnYWQ4bGl1
4 replies
KryptonResearch14 Oct 4, 12:59 AM
$PFE Pfizer presented Phase 3 vitiligo data for LITFULO yesterday at EADV in Vienna: two trials, 2,174 patients, which Pfizer says is the largest oral systemic program in nonsegmental vitiligo to date. At the 100 mg dose, 21.86% of patients hit F-VASI75 at week 52 vs 2.40% on placebo. Total-body T-VASI50 was 13.02% vs 2.40%. The 50 mg dose came in at roughly half the effect. Benefit showed up by week 24 and kept growing through week 52. One level down: Incyte's Opzelura is the only FDA-approved vitiligo treatment, and it is a topical cream limited to 10% of body surface area. A once-daily oral has no coverage ceiling. But the oral race already has two horses. AbbVie's Rinvoq just won EU approval for vitiligo and is under FDA review. Safety read clean against placebo: serious adverse events 3.4% in both arms of the larger trial. Filings to FDA and EMA are the next catalyst.
0 replies
cmhuff Oct 3, 5:39 PM
$PFE pretty happy here. Rolling covered calls out a few weeks ever few weeks Dividends keep coming in. Can't complain
0 replies
SuperGreenToday Oct 3, 3:39 AM
$PFE Share Price: $27.80 Contract Selected: Oct 30, 2026 $30 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.15 – $0.18 Potential Upside: 62% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
OnlyFibs Oct 3, 1:44 AM
$PFE | Snapshot 📊⚡• Business: Pfizer Inc. is one of the world's largest research-based biopharmaceutical companies, developing and commercializing prescription medicines, vaccines, and oncology treatments.• Financial Health & Pipeline: Growth supported by commercial oncology product integrations, commercial execution across key rare disease and vaccine franchises, and ongoing operational cost-realization initiatives.• Bias & Conviction: Bullish Macro Reclaim | High Conviction (Holding above long-term trendline breakout and all weekly MAs claimed for the first time since 2022). 🎯 Key Levels: 🐂 Bull Trigger: $28.86 / $29.00 🚀 Targets: $30.00 / $31.50 / $34.00 🛡️ Support: $27.50 / $27.00 ⚠️ Risk: $26.00 / $24.00 🔥 Volume & Flow: • 🟢 Ask-side call sweeps in 12/18 $29 Calls ($113.3K), 10/23 $29 Calls ($96.2K), and 12/18 $30 Calls ($91.3K). #PFE #stocks #finance #hovdid
0 replies
Outcomes Oct 2, 11:03 PM
$IBRX $MRNA $MRK $PFE $JNJ …..tip of the iceberg https://open.substack.com/pub/aaronsiri/p/recap-of-some-of-the-lawsuits-petitions?r=re3i2&utm_medium=ios
1 replies
Cancercrusader Oct 2, 10:59 PM
$PFE Should be sued into oblivion for the clot shot and all the lies
0 replies
Outcomes Oct 2, 8:43 PM
$IBRX $MRNA $MRK $PFE $JNJ ....'gene therapy'...hard pass. mRNA BAD. I'll prefer ANKTIVA please, thank you. https://x.com/robinmonotti/status/2090353470247202938?s=20
2 replies